[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541818":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":67,"collaborators":10,"id":69,"slug":10,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Fondazione del Piemonte per l'Oncologia","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort A:patients with high risk localized prostate cancer",null,"Cohort A:150 patients with high risk localized prostate cancer (defined as \\>cT3 or PSA \\> 20 ng\u002FmL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy\u002Fprostatectomy undergoing or who underwent curative treatment (prostatectomy\u002Fradical radiotherapy) but have not started a FU pathway.\n\nPatients within Cohort A will be followed up with PSA every 3 months for 3 years and early scans. They will also receive a blood sample for ctDNA\u002FCTC before (when feasible) and after radical treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC)","Cohort B: 100 patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months;Patients within Cohort B will be followed up with PSA and scans every 3 months. They will also receive a blood sample before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression",{"label":16,"type":10,"description":17,"interventionNames":10},"Cohort C:Patients with metastatic castration resistant prostate cancer (mCRPC) progressing","Cohort C:100-150 patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary.Patients within Cohort C will be followed up with PSA monthly and scans every 3 month. They will also receive a blood sample for ctDNA\u002FCTC before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression.",[19,23],{"name":20,"affiliation":21,"role":22},"Pasquale Rescigno, MD","Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":21,"role":22},"Sabrina Arena, PhD",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"ilaria Buondonno, PhD","CONTACT","+390119933393","ilaria.buondonno@ircc.it",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Marco Asioli","+390119933463","ufficio.trials@ircc.it",[36,56],{"facility":21,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Candiolo","Turin","10060","Italy","IT",{"type":44,"coordinates":45},"Point",[46,47],7.59812,44.95858,{"lat":47,"lon":46},[50,52,54,55],{"name":20,"role":28,"phone":10,"phoneExt":10,"email":51},"pasquale.rescigno@ircc.it",{"name":53,"role":28,"phone":29,"phoneExt":10,"email":30},"Ilaria Buondonno, PhD",{"name":20,"role":22,"phone":10,"phoneExt":10,"email":10},{"name":24,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":57,"status":37,"city":58,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"AOU San Luigi Gonzaga","Orbassano",{"type":44,"coordinates":60},[61,62],7.53813,45.00547,{"lat":62,"lon":61},[65],{"name":66,"role":28,"phone":10,"phoneExt":10,"email":10},"Francesco Porpiglia, MD",{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100541818",false,"NCT06334809","INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations","Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations","INSIDE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of prostate cancer as indicated below:\n\nCohort A: patients with high risk localized prostate cancer (defined as \\>cT3 or PSA \\> 20 ng\u002FmL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy\u002F prostatectomy undergoing or who underwent curative treatment (prostatectomy\u002F radical radiotherapy) but have not started a FU pathway.\n\nCohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months.\n\nCohort C: patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary.\n\n* Ability to understand and consent to informed consent;\n* Patient must be compliant with receiving a biopsy of the metastatic site (cohort C) and with FU assessments schedule\n\nExclusion Criteria:\n\n• Patients not willing to comply with study's procedures or fulfilling the inclusion criteria.","MALE","18 Years",{"count":79,"type":80},400,"ESTIMATED","OBSERVATIONAL","400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \\>cT3 or PSA \\> 20 ng\u002FmL or presence of ECE or SVI at mpMRI;\n\nCohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC);\n\nCohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment.",[84],"Prostate Cancer",[86,87,88,89,90],"prostate cancer","mHSPC","castration-resistant","PARP inhibitory","mCRPC","2025-06-10",{"date":93,"type":94},"2025-06-12","ACTUAL",{"date":96,"type":94},"2023-03-09",{"date":98,"type":80},"2027-12-31",{"name":5,"class":6},2]